Eloxx Pharmaceuticals (ELOX) vs Mereo BioPharma Group (MREO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Mereo BioPharma Group is the larger company by market cap ($55.9 million vs $55.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELOX | MREO |
|---|---|---|
| Share price | $13.74 | $0.3499 |
| Market cap | $55.46M | $55.88M |
| 1-day change | -9.49% | -6.74% |
| YTD return | — | -10.02% |
| 1-year return | — | -80.86% |
| 5-year return | — | -82.79% |
| P/E ratio (TTM) | 3.90 | — |
| EPS (TTM) | $3.52 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $23.40 | $2.37 |
| 52-week low | $8.20 | $0.20 |
| Distance from 52-week high | -41.28% | -85.24% |
| Analyst consensus | none | none |
| Avg. price target upside | +178.38% | +460.16% |
| Average volume | 44.52K | 4.04M |
| Shares outstanding | 4.04M | 159.69M |
| Employees | 10 | 39 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Eloxx Pharmaceuticals
ELOX stock →Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 10 employees
About Mereo BioPharma Group
MREO stock →Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2.
Health Care · Biotechnology: Pharmaceutical Preparations · 39 employees
ELOX vs MREO FAQ
Which is bigger, Eloxx Pharmaceuticals or Mereo BioPharma Group?
Mereo BioPharma Group (MREO) is larger, with a market capitalization of $55.88M compared with $55.46M for Eloxx Pharmaceuticals (ELOX).
Are Eloxx Pharmaceuticals and Mereo BioPharma Group in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Eloxx Pharmaceuticals and Biotechnology: Pharmaceutical Preparations for Mereo BioPharma Group.